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ABSTRACT
Objective To investigate the role of longitudinal
plasma neuroﬁlament heavy chain protein (NfH) levels
as an indicator of clinical progression and survival in
amyotrophic lateral sclerosis (ALS).
Methods A cross-sectional study involving 136
clinically heterogeneous patients with ALS and 104
healthy and neurological controls was extended to
include a prospective analysis of 74 of these ALS cases,
with samplings at approximately 3-month intervals in a
follow-up period of up to 3 years. We analysed the
correlation between longitudinal NfH-phosphoform levels
and disease progression. Temporal patterns of NfH
changes were evaluated using multilevel linear
regression.
Results Baseline plasma NfH levels were higher than
controls only in patients with ALS with short disease
duration to baseline sampling. Compared with controls,
fast-progressing patients with ALS, particularly those
with a short diagnostic latency and disease duration,
had higher plasma NfH levels at an early stage and
lower levels closer to end-stage disease. Lower NfH
levels between visits were associated with rapid
functional deterioration. We also detected antibodies
against NfH, NfH aggregates and NfH cleavage products.
Conclusions Disease progression in ALS involves
deﬁned trajectories of plasma NfH levels, reﬂecting
speed of neurological decline and survival. Intervisit
plasma NfH changes are also indicative of disease
progression. This study conﬁrms that longitudinal
measurements of NfH plasma levels are more informative
than cross-sectional studies, where the time of sampling
may represent a bias in the interpretation of the results.
Autoantibodies against NfH aggregates and NfH
cleavage products may explain the variable expression of
plasma NfH with disease progression.
Trail registration number NIHRID6160.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a relentless
and mostly fatal neuromuscular disorder where the
main pathological end point is the loss of motor
cells.1 Typically, there is a 9–14-month delay
between symptom onset and ﬁnal diagnosis.2–4
This diagnostic latency is one of the strongest
predictors of progression in ALS, with shorter
delays linked to a worse prognosis.5 The delay in
diagnosis impacts on the possible success of thera-
peutic trials, where it is likely that early interven-
tion, when many motor neurons are still healthy or
partially functioning, will result in the most positive
outcomes.6 Indeed, the most signiﬁcant beneﬁt of
riluzole, the only Food and Drug Administration
(FDA)-approved treatment for ALS, is observed fol-
lowing early intervention.7
Central to any clinical trial design is the discov-
ery and validation of biomarkers which reﬂect the
clinical heterogeneity of ALS, particularly the rate
of neurological decline.6 Neuroﬁlaments (Nf) have
recently emerged as ‘universal’ biomarkers of neu-
rodegeneration.8 Assembled in unique heteropoly-
mers, Nfs support cytoskeletal structures. They are
among the main by-products of axonal loss and
their phosphoforms accumulate in the perikaryon
and in axonal spheroids.9 Nf levels in cerebrospinal
ﬂuid (CSF) are higher in ALS than in other neuro-
degenerative disorders10–14 and they correlate
inversely with disease duration,15 diagnostic delay
and ALS functional rating scale revised
(ALSFRS_R) scores.14 Serial CSF sampling may not
be practical for longitudinal disease monitoring;
plasma neuroﬁlament heavy chain protein (NfH)
assays have recently shown a twofold increase of
NfH in patients16 with ALS and a good correlation
with CSF NfH levels.17 Studies investigating the
potential of Nfs as disease biomarkers have so far
involved relatively small group sizes, not represen-
tative of the ALS heterogeneity,18 and/or single
measurements followed by short follow-up periods.
Longitudinal studies of Nf expression at multiple
time points, together with the rate of neurological
decline may be a more appropriate approach to
assess the bioavailability of Nfs in relationship to
the natural development of the disease and eventu-
ally to treatment response.
In this study, we have up graded the sensitivity
of a plasma NfH assay to obtain reliable longitu-
dinal measurements in a large and heterogeneous
ALS cohort and evaluate whether this marker
could be informative of deﬁned patterns of disease
progression. We have tested plasma NfH levels
over multiple time points in a follow-up period of
up to 3 years in a subset of patients with ALS,
using a multilevel analysis of temporal changes of
this analyte in relationship to deﬁned clinimetrics.
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Patients with ALS are stratiﬁed into distinct NfH temporal pro-
ﬁles which reﬂect disease progression and duration.
METHODS
Participants and sampling
Approximately 20% of those patients with ALS approached
declined participation in the study. In most cases, patients with
ALS consented for the study shortly after diagnosis, although
recruitment was not limited to newly diagnosed cases. Exclusion
criteria included neurological comorbidities likely to affect Nf
homeostasis, including previous neurosurgical operations, per-
ipheral neuropathies and a recent history of neurotrauma.20–22
The control group included healthy controls (HCs) and neuro-
logical controls (NCs), affected by multiple sclerosis, a range of
neuropathies, compressive radiculopathies and benign fascicula-
tions and cramp syndrome (table 1, legend).
Baseline plasma samples were used for a cross-sectional study
of NfH levels. Serial blood samples and clinical information
were obtained on average every 2–4 months from 74 of the 136
patients with ALS, who accepted to donate further blood
samples after baseline sampling. No selection criteria were
applied to identify these 74 ALS individuals. Serial sampling for
each patient was continued until the last clinic attendance when
possible, although most of the follow-up samples were obtained
within 15 months from baseline sampling, with an average
follow-up period of 12.2±1 months (mean±SEM; max=39,
min=1.1; 25%=4.1 months; 75%=17.9 months). For the def-
inition of symptoms onset, clinical features suggestive of ALS,
including weakness and dysarthria, were identiﬁed through
interviews and further details obtained from medical records.
The study clinimetrics are summarised in the online
supplementary table S1 and deﬁned in the results section.
Sample analysis
Plasma samples were processed and aliquoted within 1 h of col-
lection and frozen at −80°C, following standard consensus pro-
cedures, including protocols for phase separation (EDTA-plasma
tubes, 3500 rpm 10 min at 20°C, processed within 1 h) and
storage (0.5 mL/aliquot, polypropylene tubes, screw caps, stored
at −80°).23 An in-house ELISA was used to quantify hyperpho-
sphorylated NfH (NfHSMI34) and variably phosphorylated NfH
(NfHSMI35) as previously described.24 Total NfH levels repre-
sented the sum of NfHSMI34 and NfHSMI35. For western blot
analyses, pooled plasma samples from three patients with ALS,
puriﬁed bovine NfH (bNfH) protein (US Biological;
N2160-15B) and HiMark protein standard (Invitrogen,
LC5699) on 3–8% tris-acetate gels (Invitrogen, EA0375BOX)
were used. Samples were pooled as the main purpose of the ana-
lysis was to demonstrate the presence of autoantibodies against
Nfs. The blots were probed and imaged for NfH (SMI-34R,
Covance)24; they were subsequently stripped of the NfH anti-
bodies and reprobed with antihuman IgG (Dako, P0214) fol-
lowing the manufacturer’s instructions (Abcam).
Statistical analysis
Numerical variables were summarised using mean±SEM,
median and IQR. Non-parametric analysis was used for group
comparisons (Mann–Whitney U test or Kruskal-Wallis test
where suitable) and Spearman’s rank correlation. Log rank ana-
lysis was used to compare survivals. The known date when a
patient was last reported to be alive (if lost to follow-up) was
used for censoring. Multilevel analysis was used to examine
NfH longitudinal trajectory (MLwiN V.2.27, from Stata V.13.1;
runmlwin command).25 Longitudinal patterns of total plasma
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NfH levels for the ﬁrst 15 months of the follow-up period were
evaluated using a multilevel model in three ALS progression
subgroups: slow, intermediate and fast progressors. The model
had two levels: measurement occasion (level 1), within indivi-
duals (level 2) and assumed a linear change in total NfH levels
over time. Each ALS progression group was included as a cat-
egorical ﬁxed effect and also as an interaction between the ALS
progression categories and time to assess whether the rate of
change in NfH differed by ALS progression rate. A random
intercept term was also included in the model. Fisher’s exact
test was used to examine whether increased plasma NfH levels
during disease progression were predictive of the decline in
ALSFRS_R scores. A p value of less than 0.05 was considered as
statistically signiﬁcant.
RESULTS
The demographic and clinical characteristics of our cohorts are
summarised in table 1. The median diagnostic latency for the
patients with ALS was 11.99 (IQR: 7.03, 20.98) months. There
was a strong negative correlation between diagnostic latency and
the progression rate at the last visit (PRL; (48−ALSFRS_R score
at the last visit)/duration in months between symptoms onset
and last visit; online supplementary table S1; Spearman’s r=
−0.511, p<0.0001), in line with previous observations.3
No signiﬁcant difference in plasma NfH levels between HC
and NC was observed (p=0.25, 0.51 and 0.20 for total NfH,
NfHSMI34 and NfHSMI35 respectively; Mann–Whitney U test).
Cross-sectional and longitudinal studies of plasma NfH
levels
Plasma NfH levels measured at baseline (visit 1: V1) were not
signiﬁcantly different between ALS (n=136) and control partici-
pants (n=104; p=0.20, 0.52 and 0.29, for total NfH,
NfHSMI34 and NfHSMI35; ﬁgure 1).
The cross-sectional analysis was repeated comparing four sub-
groups of patients with ALS divided by disease duration to base-
line (the time interval from symptoms onset to the baseline,
online supplementary table S1). Only the subgroup with the
shortest disease duration (≤12 months) showed higher levels of
plasma NfH compared with controls, close to statistical signiﬁ-
cance for total NfH and NfHSMI35 (p=0.06, 0.18 and 0.06, for
total NfH, NfHSMI34 and NfHSMI35, respectively; ﬁgure 1).
These ﬁndings suggest that patients with a shorter disease dur-
ation and diagnostic latency were likely to progress faster and to
have higher plasma NfH levels at baseline sampling.
We examined the longitudinal pattern of NfH plasma expres-
sion in 74 patients over a follow-up period of 15 months from
baseline (clinical characteristics detailed in table 2).
Figure 2A illustrates the plasma NfH measurements at base-
line (V1) and at the subsequent time points for the 74 patients
with ALS studied longitudinally, as well as at baseline for HC.
We also examined longitudinal total plasma NfH levels in
patients subgrouped according to the PRL, including fast ALS
progressors (ALS-Fast; PRL>1, n=18, red code), intermediate
ALS progressors (ALS-Intermediate; PRL 0.5–1, n=24; green
code) and slow ALS progressors (ALS-Slow; PRL<0.5, n=32;
blue code) in a follow-up period of 15 months from baseline
(ﬁgure 2B, left panel). Mean longitudinal plasma NfH measure-
ments (±SEM) revealed distinct patterns in the three ALS sub-
groups. In ALS-Fast patients, there was a steady decline in
plasma NfH levels in the follow-up period, while plasma NfH
levels in ALS-Slow patients remained stable during the ﬁrst
6 months and later increased as the disease progressed. In
ALS-Intermediate patients, an increase in NfH levels during the
early follow-up period was followed by a decrease towards a
later stage. Kaplan–Meier survival curves showed a clear separ-
ation of median cumulative survival between ALS-Fast and
ALS-Slow–Intermediate patients (p<0.0001; ﬁgure 2B, right
panel).
The predicted average trajectories of total plasma NfH levels
over the ﬁrst 15 months of follow-up for each of the three
patients with ALS subgroups from the multilevel model are
shown in ﬁgure 2C (solid lines), along with trajectories for
observed total plasma NfH levels for each individual patient
with ALS in each subgroup (dashed lines, ﬁgure 2C). No differ-
ence in total plasma NfH levels was observed at baseline
Figure 1 A scatter plot showing plasma neuroﬁlament heavy chain protein (NfH) levels in cross-sectional cohort. There was no signiﬁcant
difference in total plasma NfH (lime green), NfHSMI34 (strong blue) and NfHSMI35 (pure blue) between 136 patients with amyotrophic lateral sclerosis
(ALS; squares) and 104 controls (healthy and disease controls; circles). If patients with ALS were grouped according to the disease duration from
onset to baseline sampling, a trend towards an increased level of NfH-phosphoforms in patients with the shortest disease duration (0–12 months,
n=31) compared with controls was noted for total NfH (p=0.059) and for NfHSMI35 (p=0.055). Error bars: median±IQR. Mann–Whitney U test.
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between the three subgroups but there was some evidence of a
difference in the average monthly change in total plasma NfH
levels between the ALS-Slow (mean (95% CI): 0.20 (−0.47 to
0.86) ng/mL per month) and the ALS-Fast (−0.90 (−1.90 to
0.10) ng/mL per month) groups over the 15-month follow-up
period (p=0.07). There was no evidence of a difference
between the rate of change in total plasma NfH between the
ALS-Slow and the ALS-Intermediate (0.19 (−0.74 to 1.11)) ng/mL
per month) groups (p=0.99).
Changes in plasma NfH levels in the follow-up period do
not predict patterns of disease progression
Changes in NfH levels and ALSFRS_R scores in the follow-up
period developed according to four main patterns: (1) increas-
ing NfH levels with a progressive decline of ALSFRS_R scores;
(2) decreasing or no change of NfH levels with a progressive
decline of ALSFRS_R scores; (3) decreasing or no change of
NfH levels with steady ALSFRS_R scores and (4) increasing
NfH levels with steady ALSFRS_R scores. Statistical analysis
showed that increasing NfH levels did not predict deterioration
in function, expressed as a decline of ALSFRS_R scores (Fisher
exact test, p=0.07 and 0.17 for NfHSMI34 and NfHSMI35).
Changes in plasma NfH levels between visits and disease
progression
We have examined the correlation between the ALSFRS_R slope
((ALSFRS_R score at second visit −ALSFRS_R score at ﬁrst
visit)/time between visits in months) (see online supplementary
table S1), an indicator of disease progression, and the plasma
NfH levels at the later visit, using data from 206 ‘pairs’ of con-
secutive visits from our longitudinal cohort of 74 ALS indivi-
duals. The ALSFRS_R slope ranged between −9 and 3 (mean
±SEM=−0.866±1.34; median (IQR): −0.5 (−1.33, 0)). There
was a mild positive correlation between the ALSFRS_R slope
and NfHSMI34 levels (r=0.186, p=0.009; both panels, ﬁgure
3A), but no correlation between the ALSFRS_R slope and
NfHSMI35 levels (r=0.076, p=0.281; data not shown). The cor-
relation was strengthened for NfHSMI34and NfHSMI35 levels
(NfHSMI34: r=0.256, p=0.01, left panel, ﬁgure 3A; NfHSMI35:
r=0.215, p=0.032, data not shown), when only those patients
with a relatively faster progression were included in the analysis
(ALSFRS_R slope between −9 and −0.5). Lower plasma NfH
levels correlated with a faster decline in the ALSFRS_R score, in
line with our longitudinal analyses (ﬁgure 2), where patients
with ALS-F had lower plasma NfH levels during the more
advanced stages of disease and more marked (mostly negative)
ALSFRS_R slopes between visits.
Variability of NfH levels in the follow-up period
In our longitudinal ALS cohort, we have identiﬁed individuals
whose plasma NfH levels increase from V1 in the follow-up
period, reaching a maximum level (VMax) and individuals whose
plasma NfH levels decrease from V1 to minimal levels (VMin). As
shown in ﬁgure 3B, total plasma NfH levels in some patients
with ALS (n=45) at V1 were signiﬁcantly lower than their VMax
levels and similar to those in HCs. Conversely, plasma NfH levels
at V1 were signiﬁcantly higher in another subset of patients
(n=48) than the levels seen at VMin and in HCs (ﬁgure 3B).
The immune response to Nfs
Autoantibodies against neuron-speciﬁc proteins have been previ-
ously detected in peripheral blood.26–30 Our western blot ana-
lysis showed high molecular weight (MW) NfH-stained bands
(possible aggregates) in plasma from patients with ALS (second
lane from the left side of panel; ﬁgure 4), partially dissociated
into lower MW fragments by urea incubation (fourth lane from
the left side of panel; ﬁgure 4), as previously shown in
SOD1G93A mice that model ALS.24 No high MW aggregates or
low MW fragments were observed in puriﬁed bNfH (the ﬁrst
and third lanes from the left side of panel, ﬁgure 4) as previ-
ously shown.24 After reprobing of the blot with antihuman
IgGs, multiple intense bands for IgG at the same MW bands
containing NfH high MWaggregates, monomers and fragments
were detected (third lane from the right side of panel; ﬁgure 4,
black arrows). This pattern was intensiﬁed by urea treatment
(ﬁrst lane from the right side of panel). These results indicate a
colocalisation of NfH and IgG in the blot and support the
concept of an immune response to NfH in the plasma of
patients with ALS.
DISCUSSION
This study examined the role of plasma NfH phosphoforms, a
recently emerged biomarker of axonal loss, in the clinical moni-
toring of ALS. Using a large and heterogeneous cohort of
patients with ALS, we tested a sensitive plasma assay circum-
venting the need for CSF analysis and evaluated plasma NfH
levels in cross-sectional and longitudinal cohorts. Our assay
minimises the confounding effect caused by NfH aggregates (see
online supplementary ﬁgure S1), increasing NfH detection yield
in human, as previously shown in a mouse model of ALS.24 31
Table 2 Longitudinal ALS cohort: patient characteristics and stratification according to ALSFRS_R-based clinimetrics
Groups (progression
rate at the last visit;
PRL)** (Mean±SEM)
Patient
number
Time
points,
range
Age of
onsetNS
(mean
±SEM)
Gender,
F/M
Disease duration
at baseline: (onset
to baseline
sampling)**
(months; mean
±SEM)
Diagnostic
latency*
(months;
mean±SEM)
ALSFRS_R at
baseline**
(mean±SEM)
Ethnicity,
non-Caucasian
(%)
Site of
onset,
bulbar/
limb/both
ALS-Fast (1.252±0.06) 18 2–8 64.7±1.6 7/11 12.2±1.5 7.8±1.0 35.4±1.7 0 5/12/1
ALS-Intermediate
(0.706±0.02)
24 2–6 63.4±2.4 10/14 22.0±1.7 15.4±1.6 34.7±1.6 0 4/20/0
ALS-Slow (0.276±0.02) 32 2–11 61.1±1.9 6/26 29.2±2.6 17.8±2.1 41.2±1.1 5.80 8/26/1
Patients with ALS followed up longitudinally are subgrouped according to the PRL: ALS-Fast (PRL>1.0), ALS-Intermediate (PRL 0.5–1.0) and ALS-Slow (PRL<0.5). The three groups of
patients differ with regard to in the ALSFRS_R score at baseline, disease duration and diagnostic latency. There is no difference in age of between patients groups
*p<0.01, **p<0.0001, NS: not significant. Kruskal–Wallis test.
ALS, amyotrophic lateral sclerosis; ALSFRS_R, ALS functional rating scale revised; PRL, progression rate at the last visit.
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The relentless disease progression in ALS may suggest a linear
change in time of any biological signal that reﬂects the under-
lying pathological process. The SOD1G93A mouse model of
ALS, for example, displays a homogeneous and rapid disease
course, where plasma NfH levels increase towards end-stage
disease.32 The present study demonstrates that the situation in
the human pathology is completely different, not least because
of the signiﬁcant heterogeneity of the disease (ﬁgures 2B and
3B). Our study suggests that plasma NfH levels in patients with
ALS may reﬂect the speed of disease progression and the disease
duration. However, there was ultimately no difference in plasma
NfH expression between controls and ALS cases. Only a subset
of ALS individuals with the shortest disease duration and faster
progression rate showed tendentially higher but not statistically
Figure 2 (A) A scatter plot showing total plasma neuroﬁlament heavy chain protein (NfH) levels at different time points for 74 patients with
amyotrophic lateral sclerosis (ALS) in a 15-month follow-up period from baseline. Median and IQRs are shown beside the total plasma NfH levels.
(B) Left panel: longitudinal proﬁles of mean total plasma NfH levels are shown in red for ALS-Fast, in green for ALS-Intermediate and in blue for
ALS-Slow in a 15-month follow-up period. Each sampling time point is reported as the time from baseline, together with the n number of samples
from ALS-Fast, ALS-Intermediate and ALS-Slow subgroups. Error bars: ±SEM. Right panel: distinct curves representing cumulative survivals in the
total follow-up period for ALS-Fast (red lines), ALS-Intermediate (green lines) and ALS-Slow (blue lines) subgroups. (C) Trajectories of total NfH levels
in the follow-up period for individual with ALS (dashed lines) and predicted average trajectories (solid lines) are shown for ALS-Fast (red),
ALS-Intermediate (green) and ALS-Slow (blue) patients. ALS-Fast: overall progression rate >1.0; ALS-Intermediate: overall progression rate 0.5–1.0;
and ALS-Slow: overall progression rate <0.5.
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signiﬁcant NfH levels than controls at baseline (ﬁgure 1).3 A
wide range of plasma NfH levels were also observed in controls.
The variability in NfH plasma expression may reﬂect the
enhanced sensitivity of our assay, which minimises the ‘hook
effect’ due to NfH aggregation in ALS and in control plasma
samples (see online supplementary ﬁgure S1) and to the variable
effect of autoantibodies against NfH. A reduced n number after
stratiﬁcation of our ALS cohort and the signiﬁcant variability of
plasma NfH levels may explain the lack of statistical power.
While future studies with larger cohorts of ALS cases and con-
trols may add to our initial ﬁndings, our results highlight poten-
tial limitations of plasma NfH measurements as prognostic
biomarkers in ALS. An important learning point from our inves-
tigation is that the results of cross-sectional studies with limited
case numbers and more homogeneous ALS cohorts should not
be interpreted as a signature of ALS as a whole, but a random
snapshot of a deﬁned ALS phenotype and stage of disease devel-
opment at the time when the sample is taken.
The characterisation of the longitudinal proﬁles of plasma
NfH levels in our clinically heterogeneous ALS cohort was more
meaningful if the prospective NfH measurements were stratiﬁed
according to the speed of disease progression of the ALS indivi-
duals in the study. Fast progressors (ALS-Fast) appeared to have
higher plasma NfH levels during the early stages of disease, but
lower levels as they approached end stage (ﬁgure 2B, left panel);
they also had the worst cumulative survival (ﬁgure 2B, right
panel). The separation between trajectories of NfH levels in our
fast and slow progressors appeared to be more marked towards
the end of the follow-up period as our multilevel model of ana-
lysis demonstrates (ﬁgure 2C). This ﬁnding supports the import-
ance of prospective measurements of a disease biomarker as a
means to understand its true biological signiﬁcance and its
Figure 3 (A) A scatter plot showing the correlation between the amyotrophic lateral sclerosis functional rating scale revised (ALSFRS_R) slope
between consecutive visits (ALSFRS_R score second visit minus ALSFRS_R score ﬁrst visit)/time between visits in months) and the plasma NfHSMI34
levels at the later visit. There was a correlation between the ALSFRS_R slope and NfHSMI34 levels in 206 visit pairs (r=0.186, p=0.009, left and right
panels altogether), which was strengthened if only those consecutive visits recording a higher level of functional decline (ALSFRS_R slope between
−9 and −0.5; left panel only; r=0.256, p=0.01) were considered. (B) The bar chart illustrates the variability of total plasma NfH levels in the
follow-up period from baseline levels. In a subset of patients with ALS, total plasma NfH levels increase during disease progression to a maximum
level (VMax; blue bar) while in another group, they decrease to a minimum level (VMin; red bar) from the baseline levels. Comparative analyses with
control levels in cross-sectional studies would therefore be dependent on the sampling times in the disease progression. Healthy controls (HC): grey
bar. Error bars: ±SEM. **p<0.01, ***p<0.0001. Kruskal-Wallis test.
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exploitability as an indicator of disease progression. The lack of
any signiﬁcant difference in plasma NfH levels at baseline
between ALS-Fast and ALS-Slow and of steady trajectories of
expression in the longitudinal analyses argue against the use of
plasma NfH as prognostic biomarkers and as a suitable indicator
of treatment response. Plasma NfH levels appear to be a good
surrogate measure of treatment response in a predictable animal
model of ALS, where plasma NfH levels surge with the disease
progression.32 In humans, the clinical heterogeneity may impact
on NfH homeostasis, making any inference on the relationship
between plasma NfH levels, disease progression and treatment
response very difﬁcult. The observed immune response to NfH
is also likely to speed up NfH clearance and/or have a masking
effect over the epitopes recognised by the antibodies employed
in our ELISA (ﬁgure 4).
The change in plasma NfH levels between consecutive visits
may be a stronger indicator of disease progression. We observed
a weak but signiﬁcant correlation between lower plasma NfH
levels and a more marked decline in the ALSFRS_R score
between visits (a more negative slope indicates a faster progres-
sion; ﬁgure 3A). This ﬁnding appears to diverge from previous
observations which supported a correlation between high levels
of plasma and CSF NfH/NfL and a higher level of functional
impairment.14 17 These studies correlated pNfH levels at base-
line in a relatively small number of cases to the functional
deterioration observed over short follow-up periods. Our study
is more representative of the disease progression as we examine
plasma NfH levels and functional deterioration in all available
visit pairs (n=206), during a much longer follow-up period.
Differences in the methods employed for NfH detection and in
the composition of the ALS cohorts may have also played a part
in the observed differences between our study and previously
published data. Finally, it is possible that the clinical heterogen-
eity of ALS may be the main determinant of the different NfH
expression proﬁles seen in plasma. Axonal loss is likely to occur
during the unrecognised asymptomatic phase of the disease and
as a result, in ALS-Fast patients, plasma NfH levels may peak
early in the disease, decreasing later as the motor neuron popu-
lation depletes. Conversely, increasing plasma NfH levels from
initially low levels in ALS-Slow patients may reﬂect the slower
pace of neurodegeneration compared with ALS-Fast patients.
The early loss of ALS-Fast patients, due to the aggressive
nature of their disease, compared with the possibility of a more
prolonged follow-up in ALS-Slow patients is likely to represent
a bias in the statistical analysis which is central to the interpret-
ation of our data. The inevitable drop in the number of longitu-
dinal samples after baseline in ALS-Fast patients (ﬁgure 2B, left
panel) increases the size of ‘missing data’ asymmetrically com-
pared with the remaining patients with ALS, thereby reducing
the sensitivity of simple repeated measurements in our
Figure 4 Immunoblots of plasma samples from patients with amyotrophic lateral sclerosis (ALS) and of puriﬁed bovine neuroﬁlament heavy chain
protein (NfH) proteins. NfH bands represent high molecular weight (MW) aggregates (238–460 kDa), monomers and NfH fragments (bands below
∼205 kDa) in plasma samples from patients with ALS (the second lane from the left of the panel), while only a monomer band for puriﬁed bovine
NfH protein is displayed bovine NfH (bNfH, the ﬁrst lane from the left of the panel). Urea partially dissolved the high MW NfH from ALS plasma as
shown previously in superoxide dismutase1 (SOD1)G93A mice (the fourth lane from the left side of the panel), but had no effect on bNfH (the third
line form the left side of the panel; refer J Neurosci Methods). After stripping of the NfH antibodies, the blot was reprobed with antihuman IgG (the
four lanes from the right side of the panel). In ALS samples, multiple bands showing intense staining for human IgG were present at the level of
NfH high MW aggregates, NfH monomers and NfH endogenous fragments and (black arrows), but not in the bNfH lanes (the second and fourth
lanes on the right side).
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longitudinal cohort. The speciﬁc nature of ALS poses other
challenges in the analysis of any biomarker’s disease trajectory,
when compared with longitudinal studies in other neurological
disorders. Unlike acute conditions such as spinal cord injury,
which has a deﬁned onset and can be followed-up with regular
sampling during hospitalisation,33 neurodegenerative disorders
such as ALS may start and progress subclinically, making any
deﬁnition of disease onset and duration difﬁcult. A regular
pattern of follow-up and sampling of patients with ALS can also
be difﬁcult to achieve in an outpatient setting. By using a multi-
level model, we have been able to include all individuals in the
analysis under a ‘missing at random’ assumption,34 so that
inconsistencies related to the incomplete follow-up periods can
be minimised. We limited the effect of informative drop-out by
restricting analysis to the ﬁrst 15 months of follow-up. We also
found that applying the method of Touloumi et al35 to account
for informative drop-out in our multilevel model analysis did
not meaningfully change the results from those presented here.
Nevertheless, the importance of large, well characterised and
consistent longitudinal cohorts remains paramount.
Our study provides a temporal segmentation of disease trajec-
tories in ALS, based on clinical and biological measurements.
From the results of the longitudinal study presented here, it is
clear that the level of information that cross-sectional biomarker
studies can provide in ALS is limited, as the results are critically
dependent on the chosen sampling time in the study population
(ﬁgure 3B).
A longitudinal analysis of a disease-relevant molecular signal
should be included in the design of any study whenever pos-
sible. In clinical trials for example, a projected change of the
area under the curve of the longitudinal measurements is one of
the surrogate outcomes of treatment response. The a priori
knowledge of the biomarker expression during the natural
course of the disease and in its phenotypic variants would facili-
tate the recognition of treatment response. The ideal biomarker
would have higher levels of expression in ALS compared with
controls, would maintain steady levels throughout the disease
course and would reﬂect the rate of neurological decline and
the disease duration. Longitudinal analyses of plasma NfH
levels in HCs should also be considered along with NfH studies
in the general population stratiﬁed according to age, the main
risk factors for neurodegenerative disorders. The lack of condi-
tions likely to cause NfH release in our cohorts other than ALS
was used to assume a relative temporal stability of plasma NfH
levels in controls which were tested only at baseline. Future lon-
gitudinal biomarker investigations will certainly beneﬁt from
more integrated biological measurements including the analysis
of the immune response to the proteins under investigation and
by the development of multimodal investigations which would
include, for example, imaging of the neuraxis to disclose add-
itional features of axonal loss.
Author afﬁliations
1Centre for Neuroscience & Trauma, Blizard Institute, Barts and The London School
of Medicine and Dentistry, Queen Mary University of London, London, UK
2Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute
of Neurology, London, UK
3Department of Neuroinﬂammation, UCL Institute of Neurology, London, UK
4Basildon and Thurrock University Hospitals NHS Foundation Trust, Essex, UK
5MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
6National Hospital for Neurology and Neurosurgery, London, UK
7Department of Medical Statistics, London School of Hygiene and Tropical Medicine,
London, UK
8Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
9Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
10Clinical Trial Unit, Musgrove Park Hospital, Taunton, UK
11Department of Clinical Neuroscience, UCL Institute of Neurology, London, UK
12MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK
13North-East London and Essex MND Care and Research Centre, London, UK
Acknowledgements The authors thank all the participants and their families who
kindly contributed to this project as well as our funding organisations (Motor
Neurone Disease Association and Barts and The London Charity), without whose
support this project would not have been possible. The authors also would like to
thank the contribution made by Ann Cochrane, Louise Speigel, Elizabeth Jane
Homan, Danise Sharon, Sarah Green in data collection and patient enrolment.
Contributors C-L undertook the laboratory work, data analysis and interpretation,
performed the statistical analysis and wrote the ﬁrst draft of the paper. AP
contributed to the design of the study, laboratory work, statistical analyses and
revision of the manuscript. JT and KA participated in laboratory work. CMW
contributed to statistical analysis. RO, MF, KS, RH, JC and PF contributed to patient
enrolment, data collection and revised the manuscript for content. JK, NP, and GG
participated in conceptualising the study and revised the manuscript for content. LG
contributed to the conceptualisation and design of the study, data interpretation and
review and amendment of the manuscript. AM contributed to the conceptualisation
and design of the study, patient enrolment, data collection, interpretation of the
data, review and amendment of the manuscript. All the authors reviewed the drafts
and approved the ﬁnal version of this manuscript.
Funding This project was funded by The Motor Neurone Disease Association
(Malaspina/Apr13/6097) and Barts and The London Charities (468/1714). LG is the
Graham Watts Senior Research Fellow, funded by The Brain Research Trust and the
European Community’s Seventh Framework Programme (FP7/2007-2013).
Competing interests None.
Ethics approval Ethical approval was obtained from the East London and the
City Research Ethics Committee 1 (09/H0703/27) and written informed consent was
obtained from 136 ALS patients (according to the El Escorial Criteria19) and 104
controls, seen at the University College London partners Motor Neuron Disease
Clinics and at Musgrove Park Hospital, Somerset, between June 2009 and
November 2012.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Carvalho MD, Swash M. Awaji diagnostic algorithm increases sensitivity of El
Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 2009;10:53–7.
2 Cellura E, Spataro R, Taiello AC, et al. Factors affecting the diagnostic delay in
amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2012;114:550–4.
3 Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical
review. Amyotroph Lateral Scler 2009;10:310–23.
4 Iwasaki Y, Ikeda K, Ichikawa Y, et al. The diagnostic interval in amyotrophic lateral
sclerosis. Clin Neurol Neurosurg 2002;104:87–9.
5 Turner MR, Scaber J, Goodfellow JA, et al. The diagnostic pathway and prognosis in
bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci 2010;294:81–5.
6 Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis:
opportunities and limitations. Nature reviews. Neurology 2011;7:631–8.
7 Zoing MC, Burke D, Pamphlett R, et al. Riluzole therapy for motor neurone disease:
an early Australian experience (1996–2002). J Clin Neurosci 2006;13:78–83.
8 Petzold A. Neuroﬁlament phosphoforms: surrogate markers for axonal injury,
degeneration and loss. J Neurol Sci 2005;233:183–98.
9 Manetto V, Sternberger NH, Perry G, et al. Phosphorylation of neuroﬁlaments is
altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1988;47:642–53.
10 Brettschneider J, Petzold A, Sussmuth SD, et al. Axonal damage markers in
cerebrospinal ﬂuid are increased in ALS. Neurology 2006;66:852–6.
11 Ganesalingam J, An J, Shaw CE, et al. Combination of neuroﬁlament heavy chain
and complement C3 as CSF biomarkers for ALS. J Neurochem 2011;117:528–37.
12 Norgren N, Rosengren L, Stigbrand T. Elevated neuroﬁlament levels in neurological
diseases. Brain Res 2003;987:25–31.
13 Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral
sclerosis and other neurodegenerative diseases have increased levels of
neuroﬁlament protein in CSF. J Neurochem 1996;67:2013–18.
14 Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal ﬂuid neuroﬁlament
light levels in patients with amyotrophic lateral sclerosis: a possible marker of
disease severity and progression. Eur J Neurol 2012;19:1561–7.
Neurodegeneration
572 Lu C-H, et al. J Neurol Neurosurg Psychiatry 2015;86:565–573. doi:10.1136/jnnp-2014-307672
15 Zetterberg H, Jacobsson J, Rosengren L, et al. Cerebrospinal ﬂuid neuroﬁlament
light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol
2007;14:1329–33.
16 Boylan K, Yang C, Crook J, et al. Immunoreactivity of the phosphorylated axonal
neuroﬁlament H subunit (pNF-H) in blood of ALS model rodents and ALS patients:
evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem
2009;111:1182–91.
17 Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neuroﬁlament heavy subunit
(pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in
amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:467–72.
18 Chio A, Calvo A, Moglia C, et al. Phenotypic heterogeneity of amyotrophic lateral
sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011;82:740–6.
19 Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the
diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2000;1:293–9.
20 Petzold A, Keir G, Kay A, et al. Axonal damage and outcome in subarachnoid
haemorrhage. J Neurol Neurosurg Psychiatry 2006;77:753–9.
21 Petzold A, Mondria T, Kuhle J, et al. Evidence for acute neurotoxicity after
chemotherapy. Ann Neurol 2010;68:806–15.
22 Petzold A, Tisdall MM, Girbes AR, et al. In vivo monitoring of neuronal loss in
traumatic brain injury: a microdialysis study. Brain 2011;134(Pt 2):464–83.
23 Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the
standardization of cerebrospinal ﬂuid collection and biobanking. Neurology
2009;73:1914–22.
24 Lu CH, Kalmar B, Malaspina A, et al. A method to solubilise protein aggregates for
immunoassay quantiﬁcation which overcomes the neuroﬁlament “hook” effect.
J Neurosci Methods 2011;195:143–50.
25 Leckie G, Charlton C. Runmlwin: a program to run the MLwiN multilevel modeling
software from within Stata. J Stat Softw 2013;52:1–40.
26 Abou-Donia MB, Abou-Donia MM, Elmasry EM, et al. Autoantibodies to nervous
system-speciﬁc proteins are elevated in sera of ﬂight crew members: biomarkers for
nervous system injury. J Toxicol Environ Health A 2013;76:363–80.
27 Couratier P, Yi FH, Preud’homme JL, et al. Serum autoantibodies to neuroﬁlament
proteins in sporadic amyotrophic lateral sclerosis. J Neurol Sci 1998;154:137–45.
28 Fialova L, Bartos A, Svarcova J, et al. Serum and cerebrospinal ﬂuid heavy
neuroﬁlaments and antibodies against them in early multiple sclerosis.
J Neuroimmunol 2013;259:81–7.
29 Fialova L, Svarcova J, Bartos A, et al. Cerebrospinal ﬂuid and serum antibodies
against neuroﬁlaments in patients with amyotrophic lateral sclerosis. Eur J Neurol
2010;17:562–6.
30 Puentes F, Topping J, Kuhle J, et al. Immune reactivity to neuroﬁlament proteins
in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry
2014;85:274–8.
31 Stevenson L, Kelley M, Gorovits B, et al. Large molecule speciﬁc assay operation:
recommendation for best practices and harmonization from the global bioanalysis
consortium harmonization team. AAPS J 2014;16:83–8.
32 Lu CH, Petzold A, Kalmar B, et al. Plasma neuroﬁlament heavy chain levels
correlate to markers of late stage disease progression and treatment response
in SOD1 G93A mice that model ALS. PLoS ONE 2012;7:e40998.
33 Mondello S, Buki A, Italiano D, et al. α-Synuclein in CSF of patients with severe
traumatic brain injury. Neurology 2013;80:1662–8.
34 Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to
analyse unbalanced repeated measures and longitudinal data. Stat Med
1997;16:2349–80.
35 Touloumi G, Pocock SJ, Babiker AG, et al. Estimation and comparison of rates of
change in longitudinal studies with informative drop-outs. Stat Med
1999;18:1215–33.
Neurodegeneration
Lu C-H, et al. J Neurol Neurosurg Psychiatry 2015;86:565–573. doi:10.1136/jnnp-2014-307672 573
